We partner with the media to inform the public of the global human crisis.
Latest News
-
April 20, 2018
Indivior Announces New Drug Submission to Health Canada for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Moderate to Severe Opioid Use Disorder... -
April 13, 2018
Patient-Reported Outcomes Data on SUBLOCADEᵀᴹ (Buprenorphine Extended-Release) Injection to be Presented as Late-Breaker at American Society of Addiction Medicine (ASAM) 49ᵗʰ Annual Conference... -
April 11, 2018
Indivior to Announce First Quarter 2018 Results on May 2nd and Host Conference Call... -
April 5, 2018
Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers... -
March 29, 2018
Indivior Enters Into an Exclusive Global License Agreement for C4X Discovery’s Orexin-1 (OX1) Antagonist Program...
Global Media Contacts
Email: IndiviorMediaContacts@indivior.com
Phone: +1 804-594-0836
UK Media Contacts
Tulchan Communications LLP
85 Fleet Street
London
EC4Y 1AE
Indivior@Tulchangroup.com
Phone: +44 (020) 7353 4200
Upcoming Events
Media Kit
The Online Press Kit is designed to help media research our company for background information or follow-up stories. Please visit the links below to learn more.
About Indivior PLC – An overview of Indivior, including our worldwide locations and key products
Board of Directors – Biographies of Indivior’s Board
The Indivior PLC Pipeline – Information about the Indivior R&D efforts and progress of medicines in the pipeline